Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple‑negative breast cancer cells

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)839-847
JournalInternational Journal of Oncology
StatePublished - Jan 22 2013

Fingerprint Dive into the research topics of 'Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple‑negative breast cancer cells'. Together they form a unique fingerprint.

Cite this